Vasospasm (VSP) is one of the major causes for prolonged neurologic deficit in patients with aneurysmal subarachnoid hemorrhage
The combination of iHTN and IAN can dramatically increase vasopressor demand
Nimodipine was infused intra-arterially via a diagnostic catheter in the internal carotid artery or vertebral artery at a rate of 0
Keywords: case report, intra-arterial infusion, vasospasm, subarachnoid haemorrhage, intracranial aneurysm Go to: Introduction Continuous intraarterial nimodipine infusion (CIAN) is a promising approach in patients with intracranial large vessel vasospasm (LVV)
Methods: Patients from two centers ( n = 718) treated for SAH between 2008 and 2016 were included
Peer Review reports Introduction Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a neuroradiological method to help differentiate from primary central nervous system vasculitis
At our institution, Rigshospitalet, IAN treatment has been used since 2009, but the short- and long-term clinical efficacy of IAN has not yet been assessed
We report about a case series of continuous intra-arterial infusion of the calcium channel antagonist nimodipine for 1-5 days on the intensive care unit
Conclusion Intra-arterial spasmolysis using nimodipine infusion was associated with low treatment specific complications
We report our initial experience with intra-arterial use of a calcium channel blocker, nicardipine
However, patients with vasospasms and NM treatment show higher infarct growth resulting in lower ASPECTS in follow-up imaging
Material and methods: Fifty-three patients who developed vasospasm following aSAH were included in the study
Intra-arterial treatment, including nimodipine, has been studied, but only as retrospective and single-arm prospective studies
3 In patients not responding to this preventive therapy, short local intra-arterial nimodipine administration (SLINA) is recommended, although it is often Background Long-term continuous intra-arterial nimodipine infusion (CIAN) is a rescue therapy option in cases of severe refractory cerebral vasospasm (CV) following acute non-traumatic subarachnoid hemorrhage (SAH)
18,34-36 The intra-arterial administration Here, we tested the hypothesis that angiographic response to intra-arterial nimodipine application may be helpful in differentiating between RCVS and other entities
87 days
Conclusions: A majority of patients developed an ischaemic cerebral infarction in spite of intra-arterial nimodipine treatment
used intra-arterial nimodipine for treatment of CV and found angiographic improvement in 43% of patients and clinical improvement in 76% of patients
An intra-arterial application of nimodipine has been shown to increase the vessel diameter, although this effect is transient
We analyzed angiographic IAN response in a detailed vessel-specific manner and examined the impact of After initial intra-arterial infusion of nimodipine (1-2 mg within 10-15 minutes), they underwent occlusion of the aneurysm with coils under continuous intra-arterial infusion of nimodipine at a dose of 1 mg per hour
Background: Oral nimodipine is used for prophylaxis and treatment of delayed cerebral ischemia in patients with aneurysmal or perimesencephalic subarachnoid hemorrhage (SAH)
Because of angiographic vasospasm, an intra-arterial nimodipine application was performed in only one case in cohort 1
Patients, who suffered from specific focal neurologic deficit without impairment of consciousness, were awakened Background: Cerebral vasospasm (CV) is a potentially disastrous consequence of subarachnoid hemorrhage despite medical treatment
Magnesium supplementation to prevent hypomagnesaemia should be employed
The goal of the present study was to investigate the clinical effect and cerebral perfusion after IAN in patients with severe vasospasm refractory to hemodynamic treatment
Neurocrit Care
Transient hypotension and bradycardia are the only reported adverse effects of IAN
Methods: We retrospectively reviewed the procedure reports, anaesthetic records, clinical charts and CT and angiographic images of 9 patients who had received intra-arterial nimodipine; 1 of these patients received both nimodipine and The authors present a case of severe refractory vasospasm successfully treated with continuous intra-arterial nimodipine infusion
Intra-arterial nimodipine infusion is an effective and safe treatment for symptomatic vasospasm
Abstract BACKGROUND AND PURPOSE: The efficacy of intra-arterial administration of nimodipine (IAN) in patients with severe vasospasm after aneurysmal subarachnoid
In 2009, one prospective randomized clinical trial showed no
intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage
Four (8%) patients died within 30 days
Intra-arterial nimodipine (IAN) has shown a promising effect on cerebral vasospasm (CV) after aneurysmal subarachnoid haemorrhage
We compared the outcomes between CV patients who received an adjunct intra-arterial nimodipine infusion (IANI) and those who received the standard medical treatment alone in a prospective randomized controlled trial
Finally, PACNS was diagnosed, which was also supported by the finding of a CSF pleocytosis
However, these have mainly moderate character and do not directly affect the functional Intra-arterial nimodipine application in iatrogenic vasospasms during endovascular stroke treatment is angiographically speaking an effective treatment without increasing the rate of intracranial hemorrhage in this study
Retrospective
2422
Neurological outcome (modified Rankin Scale) at 30 days and 6 months, development of cerebral infarction after intra-arterial nimodipine treatment and procedure-related Consequently, intra-arterial microcatheters were placed into the petrosal part of both ICAs for continuous intra-arterial vasospasmolysis with nimodipine (0
Effective treatment of vasospasm is therefore one of the main priorities for these patients
Methods A total of 25 consecutive patients who received intra-arterial milrinone and nimodipine treatment for CV following SAH between 2014 and 2017 were included in the study
The purpose of this study is to examine the radiation exposure and to determine local diagnostic reference levels (DRLs) of intra-arterial nimodipine therapy
Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results